Sudden‐Onset Sensorineural Hearing Loss after Immunization

Baxter, Roger; Lewis, Ned; Bohrer, Pamela S.; Harrington, Theresa; Aukes, Laurie; Klein, Nicola P.

doi:10.1177/0194599816639043

Cited by 33 publications

(33 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies published before the COVID-19 pandemic, none with data regarding the novel mRNA vaccines, reviewed over 20 million vaccine doses given, and did not find any association between vaccination and sudden hearing loss ( 7 ). We present our data from a busy otologic practice after noticing an increase in patients presenting with SSNHL, or increased exacerbations of inner ear disease in formerly stable patients.…”

Section: Discussionmentioning

confidence: 99%

Otologic Manifestations After COVID-19 Vaccination: The House Ear Clinic Experience

Wichova

Miller

Derebery

2021

Otology &Amp; Neurotology

103

View full text Add to dashboard Cite

Objective: With the increasing numbers of COVID-19 vaccinations available there are some reports of new onset of otologic symptoms. We present our experience in recently vaccinated patients over a 30-day time frame. Study Design: Retrospective chart review. Setting: Tertiary otology ambulatory practice. Patients: All patients with available diagnostic codes, COVID-19 questionnaires and clinical notes. Interventions: Observational recordings. Main Outcome Measures: Within the same 30-day time period in 2019, 2020, and 2021, 1.6, 2.4, and 3.8% respectively, of all office visits were for patients with the diagnosis of new onset idiopathic sensorineural hearing loss (SNHL) without other underlying otologic diagnoses. In this time frame in 2021, 30 patients out of the 1,325 clinical visits had new or significantly exacerbated otologic symptoms that began shortly after COVID-19 vaccination. Specifically, 18 patients received Moderna and 12 patients received Pfizer vaccine. Their mean age was 60.9±13.8 years old; 11 were women and 19 men. The mean onset of symptoms was 10.18 ± 9 days post-vaccination. Symptoms included 25 patients (83.3%) with hearing loss, 15 (50%) with tinnitus, eight (26.7%) with dizziness, and five (16.7%) with vertigo. Eleven patients had previous otologic diagnoses, including six patients with Menière's disease, two with autoimmune inner ear disease (AIED), and three having both. Conclusions: There are no definite correlations to the COVID-19 pandemic or vaccination and new or worsened otologic symptoms. Vaccinated patients with new or exacerbated otologic symptoms should be promptly referred for evaluation. Suspected cases of post-vaccination otologic symptoms should be reported to the Center for Disease Control (CDC) vaccine adverse event reporting system (VAERS).

show abstract

Section: Discussionmentioning

confidence: 99%

Otologic Manifestations After COVID-19 Vaccination: The House Ear Clinic Experience

Wichova

Miller

Derebery

2021

Otology &Amp; Neurotology

103

View full text Add to dashboard Cite

show abstract

“…During early postlicensure surveillance, several adverse events following HepB vaccination have been described in the scientific literature, including Guillain-Barré Syndrome (GBS), chronic fatigue syndrome, optic neuritis, multiple sclerosis, and diabetes mellitus; however, multiple studies have demonstrated no association between receipt of HepB vaccine and these conditions ( 126 – 129 ). In addition, no evidence of a causal association between rheumatoid arthritis ( 130 ), Bell’s palsy ( 131 ), autoimmune thyroid disease ( 132 ), hemolytic anemia in children ( 133 ), anaphylaxis ( 134 ), optic neuritis ( 135 ), Guillain-Barré Syndrome ( 136 ), sudden-onset sensorineural hearing loss ( 137 ), or other chronic illnesses and receipt of HepB vaccine has been demonstrated through analysis of VSD data.…”

Section: Prophylaxis Against Hbv Infectionmentioning

confidence: 99%

Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices

et al. 2018

View full text Add to dashboard Cite

Summary Hepatitis B virus (HBV) is transmitted via blood or sexual contact. Persons with chronic HBV infection are at increased risk for cirrhosis and liver cancer and require medical care. This report updates and summarizes previously published recommendations from the Advisory Committee on Immunization Practices (ACIP) and CDC regarding the prevention of HBV infection in the United States. ACIP recommends testing all pregnant women for hepatitis B surface antigen (HBsAg), and testing HBsAg-positive pregnant women for hepatitis B virus deoxyribonucleic acid (HBV DNA); administration of HepB vaccine and hepatitis B immune globulin (HBIG) for infants born to HBV-infected women within 12 hours of birth, followed by completion of the vaccine series and postvaccination serologic testing; universal hepatitis B vaccination within 24 hours of birth, followed by completion of the vaccine series; and vaccination of children and adolescents aged <19 years who have not been vaccinated previously. ACIP recommends vaccination of adults at risk for HBV infection, including universal vaccination of adults in settings in which a high proportion have risk factors for HBV infection and vaccination of adults requesting protection from HBV without acknowledgment of a specific risk factor. These recommendations also provide CDC guidance for postexposure prophylaxis following occupational and other exposures. This report also briefly summarizes previously published American Association for the Study of Liver Diseasest guidelines for maternal antiviral therapy to reduce perinatal HBV transmission

show abstract

“…Several cases have been published, particularly regarding meningitis, tetanus and diphtheria vaccines , hepatitis B vaccine with complete recovery after 6 months , flu vaccine and the MMR vaccine . Conversely, Baxter et al analyzed cases of hearing loss after the administration of different vaccines from 2007 to 2013 and did not evidence any correlation between the two events. In order explain the ototoxicity of the hepatitis B vaccine, a link was suggested with immunological dysfunction of the inner ear involving the endolymphatic sac .…”

Section: Discussionmentioning

confidence: 99%

Drug‐induced hearing loss: a case/non‐case study in the French pharmacovigilance database

Favrelière

Delaunay

Lebreton³

et al. 2020

Fundamemntal Clinical Pharma

View full text Add to dashboard Cite

Non-cases were all reports over the same period. We calculated the reporting odds ratio (ROR) with 95% confidence intervals. Among the 555 reports of hearing loss, significant RORs were found for 68 drugs. The main therapeutic classes implicated were antineoplastic agents (n = 240), systemic anti-infective agents (n = 182), immunosuppressants (n = 42) loop diuretics (n = 26), and salicylate analgesics (n = 26). We found signals of hearing loss with azacitidine, vaccines and nevirapine, immunosuppressants such as leflunomide, and biotherapies such as panitumumab and vandetanib. Prescribers should be informed about the potential associations with all these drugs. The role of the pathology itself and the known ototoxic drugs that can be associated do not allow to conclude definitively. Audiograms for the early detection of hearing loss induced by drugs known to be ototoxic are rarely carried out. Preventive treatments exist and must be considered.

show abstract

Sudden‐Onset Sensorineural Hearing Loss after Immunization

Abstract: A large-scale analysis applying a case-centered method did not detect any association between SSHL and previous receipt of TIV or other vaccines.

Cited by 33 publications

References 21 publications

Otologic Manifestations After COVID-19 Vaccination: The House Ear Clinic Experience

Otologic Manifestations After COVID-19 Vaccination: The House Ear Clinic Experience

Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices

Drug‐induced hearing loss: a case/non‐case study in the French pharmacovigilance database

Contact Info

Product

Resources

About